The efficacy and safety of aprotinin use in cardiac surgery

Annals of Thoracic Surgery

Volumn 66, Issue 5 SUPPL., 1998, Pages

  Rich, Jeffrey B ^a,b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Mid Atlantic Cardiothoracic Surgeons   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; HEMOGLOBIN; PLACEBO; SERINE PROTEINASE INHIBITOR;

AORTA ARCH; BLEEDING; BLOOD BANK; BLOOD STORAGE; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; DRUG SAFETY; GRAFT PATENCY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART SURGERY; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; REOPERATION; SURGICAL TECHNIQUE;

APROTININ; CARDIOPULMONARY BYPASS; CLINICAL TRIALS; CORONARY ARTERY BYPASS; CORONARY DISEASE; HEART VALVE DISEASES; HEMOSTASIS, SURGICAL; HUMANS; RISK MANAGEMENT;

EID: 0032443031     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(98)00964-3     Document Type: Conference Paper

References (20)

1. Kraut E., Frey E., Werle E. Über die Inaktivierung des Kallikreins. Hoppe-Seyler's Physiol Chem. 192:1930;1-21.
2. Kunitz M., Northrop J. Isolation from beef pancreas of crystalline trypsinogen, trypsin, atrypsin inhibitor and an inhibitor trypsin compound. J Gen Physiol. 19:1936;991-1007.
3. Royston D., Bidstrup B.P., Taylor K.M., Sapsford R.N. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet. 2:1987;1289-1291.
4. Dietrich D., Barankay A., Hahnel C., Richter J. High-dose aprotinin in cardiac surgery three years' experience in 1784 patients . J Cardiothorac Vasc Anesth. 6:1992;936-941.
5. Lemmer J.H. Jr, Stanford W., Bonney S.L., et al. Aprotinin for coronary bypass operations efficacy, safety, and influence on early saphenous vein graft patency: a multicenter, randomized, double-blind, placebo-controlled study . J Thorac Cardiovasc Surg. 107:1994;543-553.
6. Levy J.H., Pifarre R., Schaff H.V., et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation. 92:1995;2236-2244.
7. Lemmer J.H., Dilling E.W., Morton J.R., et al. Aprotinin for primary coronary artery bypass grafting a multicenter trial of three dose regimens . Ann Thorac Surg. 62:1996;1659-1668.
8. Hill G.E., Alonso A., Spurzem J.R., Stammers A.H., Robbins R.A. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg. 110:1995;1658-1662.
9. Royston D. Preventing the inflammatory response to open-heart surgery the role of aprotinin and other protease inhibitors . Int J Cardiol. 53:(Suppl):1996;S11-S37.
10. Lemmer J.H. Jr, Stanford W., Bonney S.L., et al. Aprotinin for coronary artery bypass grafting effect on postoperative renal function . Ann Thorac Surg. 59:1995;132-136.
11. Sundt T.D., Kouchoukos N.T., Saffitz J.E., Murphy S.F., Wareing T.H., Stahl D.J. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg. 55:1993;1418-1424.
12. Godet G., Fleron M.-H., Vicaut E., et al. Risk factors for acute postoperative renal failure in thoracic or thoracoabdominal aortic surgery a prospective study . Anesth Analg. 85:1997;1227-1232.
13. Ehrlich M., Grabenwoger M., Cartes-Zumelzu F., et al. Operations on the thoracic aorta and hypothermic circulatory arrest is aprotinin safe? J Thorac Cardiovasc Surg. 115:1998;220-225.
14. Cosgrove D.M. III, Heric B., Lytle B.W., et al. Aprotinin therapy for reoperative myocardial revascularization a placebo-controlled study . Ann Thorac Surg. 54:1992;1031-1036.
15. Smith P.K., Muhlbaier L.H. Aprotinin safe and effective only with the full-dose regimen [Editorial; comment] . Ann Thorac Surg. 62:1996;1575-1577.
16. Bidstrup B.P., Underwood S.R., Sapsford R.N., Streets E.M. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg. 105:1993;147-152.
17. Kalangos A., Tayyareci G., Pretre R., Di Dio P., Sezerman O. Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization. Eur J Cardiothorac Surg. 8:1994;651-656.
18. Havel M., Grabenwoger F., Schneider J., et al. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg. 107:1994;807-810.
19. Lass M., Welz A., Kochs M., Mayer G., Schwandt M., Hannekum A. Aprotinin in elective primary bypass surgery. Graft patency and clinical efficacy. Eur J Cardiothorac Surg. 9:1995;206-210.
20. Dietrich W., Spath P., Ebell A., Richter J.A. Prevalence of anaphylactic reactions to aprotinin analysis of two hundred forty-eight reexposures to aprotinin in heart operations . J Thorac Cardiovasc Surg. 113:1997;194-201.